MARIJUANA PHARMACOTHERAPIES: CONTROLLED CLINICAL TRIALS

描述：(申请人摘要) 大麻制剂是世界上最常用的非法物质 美国。近年来，大麻的使用率以及对大麻的依赖 一直在上升，特别是在年轻人中。大量和长期使用 大麻带来了相当大的发病率。在未来的岁月里，大麻 依赖可能会成为一个更严重、更普遍的健康问题。 相较于其他物质的滥用，治疗重而慢性 大麻的使用(依赖)受到的调查相对较少。 针对大麻依赖的对照治疗试验很少。近期 动物和人类实验室研究的特点是大量的戒断 与突然停止大麻有关的症状。这些症状是 以一系列影响为特征的，包括焦虑、易怒、躯体 抱怨，入睡困难。与大麻有关的症状 戒烟类似于抑郁症和尼古丁戒断，这表明 药物干预的效用。我们提出了一个精心构建的 测试安非他酮和安慰剂两种药物的双盲安慰剂对照试验 奈法唑酮，在心理社会干预的背景下。我们假设 减少戒断症状将导致更大的治疗留存率和 在寻求大麻使用者的治疗中导致更高的戒断率。

DESCRIPTION: (Applicant's Abstract) Cannabis preparations are the most commonly used illicit substances in the United States. In recent years, rates of marijuana use and, in turn, dependence have been rising, especially among younger people. Heavy and chronic use of marijuana carries with it substantial morbidity. In the years to come, cannabis dependence will likely become an even more severe and prevalent health problem. Compared to other substances of abuse, the treatment of heavy and chronic marijuana use (dependence) has received comparatively little investigation. There are very few controlled treatment trials for cannabis dependence. Recent animal and human laboratory studies have characterized substantial withdrawal symptoms associated with the abrupt cessation of marijuana. These symptoms are characterized by a range of effects that include anxiety, irritability, somatic complaints, and difficulty sleeping. The symptoms associated with marijuana withdrawal resemble both depression and nicotine withdrawal, suggesting the utility of a pharmacological intervention. We propose a carefully constructed double-blind placebo-controlled trial testing two agents, bupropion and nefazodone, in the context of psychosocial intervention. We hypothesize that reducing withdrawal symptoms will result in greater retention in treatment and lead to higher rates of abstinence in treatment seeking marijuana users.